{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:00:24Z","timestamp":1793520024555,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.gim.2022.10.010","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:30:26Z","timestamp":1671582626000},"page":"100328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-909X","authenticated-orcid":false,"given":"Priya S.","family":"Kishnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Broomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Houn","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Labarthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Grace","family":"Prakalapakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina An","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Zaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9646","key":"10.1016\/j.gim.2022.10.010_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gim.2022.10.010_bib2","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Pompe disease: glycogen storage disease type II, acid \u03b1-glucosidase (acid maltase) deficiency","author":"Reuser","year":"2018"},{"issue":"suppl 3","key":"10.1016\/j.gim.2022.10.010_bib3","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1007\/s10545-010-9179-2","article-title":"Antenatal diagnosis of Pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy","volume":"33","author":"Hamdan","year":"2010","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.gim.2022.10.010_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A\u00a0retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.gim.2022.10.010_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpeds.2019.08.058","article-title":"Clinical and molecular disease spectrum and outcomes in patients with infantile-onset Pompe disease","volume":"216","author":"Gupta","year":"2020","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.gim.2022.10.010_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.gim.2022.10.010_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr Neonatol"},{"issue":"4","key":"10.1016\/j.gim.2022.10.010_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"Suppl 1","key":"10.1016\/j.gim.2022.10.010_bib9","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.gim.2022.10.010_bib12","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.gim.2022.10.010_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2022.10.010_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2022.10.010_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.10.010_bib16","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"5","key":"10.1016\/j.gim.2022.10.010_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2022.10.010_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2022.10.010_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.gim.2022.10.010_bib20","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J\u00a0Biol Chem"},{"issue":"12","key":"10.1016\/j.gim.2022.10.010_bib21","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1016\/j.gim.2022.10.010_bib22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.gim.2022.10.010_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.gim.2022.10.010_bib24","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.ymgme.2019.11.107","article-title":"NEO1 and NEO-EXT studies: long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients","volume":"129","author":"Dimachkie","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"12","key":"10.1016\/j.gim.2022.10.010_bib25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.gim.2022.10.010_bib26","unstructured":"Genzyme Corporation. NEXVIAZYME\u2122 (avalglucosidase alfa-ngpt) for injection, for intravenous use. Prescribing Information. Initial US approval 2021. Revised August 2021. Accessed November 29, 2022. https:\/\/products.sanofi.us\/nexviazyme\/nexviazyme.pdf"},{"issue":"10","key":"10.1016\/j.gim.2022.10.010_bib27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/gim.2018.2","article-title":"Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study","volume":"20","author":"Hahn","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2022.10.010_bib28","first-page":"1","article-title":"Pompe disease treatment with twice a week high dose alglucoside alfa in a patient with severe dilated cardiomyopathy","volume":"16","author":"Landis","year":"2018","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.gim.2022.10.010_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNO.0b013e3181ce162a","article-title":"Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease","volume":"30","author":"Yanovitch","year":"2010","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"7","key":"10.1016\/j.gim.2022.10.010_bib30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/GIM.0b013e3181a87867","article-title":"Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker","volume":"11","author":"Young","year":"2009","journal-title":"Genet Med"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022009960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022009960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:56:26Z","timestamp":1761098186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360022009960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1098360022009960"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2022.10.010","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2022.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"100328"}}